0001179110-18-003644.txt : 20180306
0001179110-18-003644.hdr.sgml : 20180306
20180306165549
ACCESSION NUMBER: 0001179110-18-003644
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180302
FILED AS OF DATE: 20180306
DATE AS OF CHANGE: 20180306
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Albers Jeffrey W.
CENTRAL INDEX KEY: 0001638474
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37359
FILM NUMBER: 18670636
MAIL ADDRESS:
STREET 1: BLUEPRINT MEDICINES CORP.
STREET 2: 215 FIRST STREET, SUITE 340/350
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Blueprint Medicines Corp
CENTRAL INDEX KEY: 0001597264
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 45 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-374-7580
MAIL ADDRESS:
STREET 1: 45 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
edgar.xml
FORM 4 -
X0306
4
2018-03-02
0
0001597264
Blueprint Medicines Corp
BPMC
0001638474
Albers Jeffrey W.
C/O BLUEPRINT MEDICINES CORPORATION
45 SIDNEY STREET
CAMBRIDGE
MA
02139
1
1
0
0
CEO and President
Common Stock
2018-03-02
4
M
0
20000
1.87
A
20000
D
Common Stock
2018-03-02
4
S
0
6022
94.79
D
13978
D
Common Stock
2018-03-02
4
S
0
3794
93.89
D
10184
D
Common Stock
2018-03-02
4
S
0
1900
92.76
D
8284
D
Common Stock
2018-03-02
4
S
0
4100
91.66
D
4184
D
Common Stock
2018-03-02
4
S
0
600
90.52
D
3584
D
Common Stock
2018-03-02
4
S
0
2284
89.07
D
1300
D
Common Stock
2018-03-02
4
S
0
1300
88.17
D
0
D
Stock Option (Right to Buy)
1.87
2018-03-02
4
M
0
20000
0
D
2024-07-30
Common Stock
20000
975034
D
The exercise reported on this Form 4 was effected pursuant to a trading plan adopted on December 17, 2016, as amended December 20, 2017, pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 17, 2016, as amended December 20, 2017, pursuant to Rule 10b5-1 under the Exchange Act.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.31 to $95.30 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (9) to this Form 4.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.37 to $94.30 per share.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.44 to $93.25 per share.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.32 to $92.24 per share.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.33 to $90.74 per share.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.63 to $89.50 per share.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.79 to $88.48 per share.
This option was granted on July 30, 2014. This option vests as follows: (i) 42,845 shares vested in four installments at a rate of 6,974 shares on September 21, 2016, and 11,957 shares on each of October 21, 2016 and November 21, 2016, and 11,957 on December 21, 2016; (ii) 90,010 shares vested in eight installments at a rate of 6,311 shares on May 21, 2017 and 11,957 shares on each of June 21, 2017, July 21, 2017, August 21, 2017, September 21, 2017, October 21, 2017, November 21, 2017 and December 21, 2017; and (iii) 30,225 shares vest in three installments at a rate of 6,311 shares on May 21, 2018, 11,957 shares on June 21, 2018 and 11,957 shares on July 21, 2018.
/s/ Christopher Frankenfield, Attorney-in-Fact
2018-03-06